TNFRSF8 and diffuse large B-cell lymphoma: Due to factors including difficulties in the standardization of the IHC staining method and evaluation of the results, there has been a wide range of reported incidence of CD30 (9.6% to 21%) among DLBCL samples[10, 11, 22].In our study, approximately 15.7% of the DLBCL patients were classified as CD30-positive using 20% as a cut-off value in our study.